x

Posted 13 June, 2023

ILLUMINA, INC. appointed Charles Dadswell as new CEO

Nasdaq:ILMN appointed new Chief Executive Officer Charles Dadswell in a 8-K filed on 13 June, 2023.


  On June 11, 2023, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") accepted the resignation of Francis deSouza, which Mr. deSouza submitted to the Board on June 8, 2023, as Chief Executive Officer and as a director of the Company, effective immediately, and the Board appointed Charles Dadswell, the Company's current Senior Vice President and General Counsel, to serve as interim Chief Executive Officer, effective immediately, until the Board's search for a permanent Chief Executive Officer is completed.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of ILLUMINA, INC.
Health Care/Life Sciences • Biotechnology
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Market Cap
$13.6B
View Company Details
ILLUMINA, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On June 11, 2023, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") accepted the resignation of Francis deSouza, which Mr. deSouza submitted to the Board on June 8, 2023, as Chief Executive Officer and as a director of the Company, effective immediately, and the Board appointed Charles Dadswell, the Company's current Senior Vice President and General Counsel, to serve as interim Chief Executive Officer, effective immediately, until the Board's search for a permanent Chief Executive Officer is completed. Mr. Dadswell will also continue to serve as the Company's Senior Vice President and General Counsel. Mr. deSouza will continue to serve in an advisory capacity to the Company until July 31, 2023. Accordingly, the Board reduced its size to ten (10) members.


Mr. Dadswell, 65, has served as Senior Vice President and General Counsel of the Company since April 2013. At this time, the Company has not entered into, amended, or modified any plan, contract, agreement, grant or award in connection with the Board's appointment of Mr. Dadswell to serve as interim Chief Executive Officer. Mr. Dadswell has no family relationship with any directors or executive officers of the Company, nor are there any arrangements or understandings between Mr. Dadswell and any other persons pursuant to which he was selected as an officer of the Company. There are no related party transactions between Mr. Dadswell and the Company reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K.


A copy of the press release announcing the Company's Chief Executive Officer transition plan is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.